1 citations
,
April 2024 in “Journal of Pharmaceutical and Pharmacological Sciences” This study evaluated androgen-induced hair loss and anagen induction mouse models, finding that Minoxidil and Pyrilutamide significantly promoted hair growth by decreasing androgen receptor protein levels and enhancing the Wnt/β-Catenin signaling pathway, supporting their use in studying novel treatments for androgenetic alopecia.
1 citations
,
July 2022 in “JEADV Clinical Practice” This abstract outlines a guide reviewing both FDA-approved and off-label therapies for androgenetic alopecia and proposes treatment algorithms based on scientific research, highlighting a gap in common treatments for this prevalent condition.
In this study, the researchers reported that the optimized compound 39 demonstrated potent AR antagonism and favorable pharmacokinetics in a hair-growth mouse model, achieving similar efficacy to pyrilutamide with faster onset and preserved safety, offering promise for next-generation topical AR antagonist development.
This study found that the optimized topical AR antagonist 39, derived from 14-P1, demonstrated potent AR antagonism and comparable efficacy to pyrilutamide in a hair-growth mouse model, with a faster onset and favorable safety profile.
In this study, researchers optimized the soft drug AR antagonist 14-P1 to create candidate 39, which demonstrated effective AR antagonism and safety in a hair-growth mouse model, showing similar efficacy to pyrilutamide but with quicker onset and a lower risk of systemic toxicity.
In a hair-growth mouse model, this study reported that the novel AR antagonist candidate 39, derived from structural optimization of 14-P1, achieved similar efficacy to pyrilutamide with faster response and maintained safety, demonstrating potent AR antagonism and favorable pharmacokinetics with lower systemic toxicity risk.
This study found that the optimized AR antagonist compound 39 showed potent hair growth activity with improved safety in mice, suggesting potential for better topical treatments for androgenetic alopecia.
In a mouse hair-growth model, this study found that the optimized compound 39 matched the efficacy of pyrilutamide for androgenic alopecia, with faster response and maintained safety, suggesting it as a promising topical AR antagonist with reduced systemic toxicity risk.
In this study, a dual soft drug design strategy improved the AR antagonist candidate 39, showing potent AR antagonism and good safety in a mouse hair-growth model, with similar efficacy to pyrilutamide but faster response.
This study found that the optimized AR antagonist candidate 39, in a hair-growth mouse model, achieved similar efficacy to pyrilutamide with faster onset and favorable safety, suggesting a promising approach for developing topical treatments with low systemic toxicity for androgenetic alopecia.
This study reports that the newly optimized AR antagonist 39 demonstrated effective hair growth and safety in a mouse model of androgenetic alopecia, showing comparable efficacy to pyrilutamide with faster response and favorable pharmacokinetics, due to innovative structural design and dual metabolic inactivation strategy.
July 2026 in “Journal of Medicinal Chemistry” In this study, candidate compound 39 demonstrated potent androgen receptor antagonism and faster hair-growth efficacy in a mouse model compared to pyrilutamide, while maintaining favorable safety and pharmacokinetic profiles, suggesting potential for topical use in androgenic alopecia.
December 2025 in “International Journal of Innovative Technologies in Social Science” This review identified emerging therapies for androgenetic alopecia, such as low-dose oral minoxidil and stem cell-based treatments, which show promise for improved hair loss management but require standardized protocols and large-scale trials for further validation.
This study performed a bibliometric analysis of the 100 most cited articles on androgenetic alopecia from 1975 to 2024, revealing that U.S. authors contributed most and highlighting a trend toward research focused on treatment options, especially between 2020 and 2024.
July 2024 in “Forum Dermatologicum” This review evaluates various topical treatments for androgenetic alopecia but does not provide new clinical findings, emphasizing the need for selecting therapies with limited systemic side effects.
This comprehensive review analyzes androgenetic alopecia treatments, discussing the mechanisms, costs, efficacy, and safety of FDA-approved drugs like minoxidil and finasteride, as well as newer non-FDA-approved options that have shown effectiveness across various studies.
August 2025 in “Journal of Cosmetic Dermatology” In this bibliometric analysis, researchers found an increasing focus on innovative treatments for androgenetic alopecia, such as platelet-rich plasma and stem cell therapy, with the United States and China leading in research contributions between 2003 and 2023.
June 2026 in “Expert Opinion on Pharmacotherapy” This article reviews emerging therapies for androgenetic alopecia, highlighting advances like androgen-receptor antagonists and improved minoxidil delivery that aim to enhance treatment efficacy and safety.
March 2026 in “Frontiers in Pharmacology” This study reviews new treatments for androgenetic alopecia, including cell-derived exosomes and investigational drugs, which show potential to improve hair density and quality but require more rigorous and standardized trials to confirm efficacy and safety.
December 2025 in “IP Indian Journal of Clinical and Experimental Dermatology” This review reports that the treatment of androgenetic alopecia is shifting from single therapies to personalized, multimodal approaches incorporating both traditional and emerging pharmacologics, regenerative strategies, nutraceuticals, cosmeceuticals, and device-based interventions, with combination regimens showing improved outcomes.
3 citations
,
November 1998 in “PubMed” This study found that finasteride significantly inhibits the metabolism of tirilazad to its active metabolites without greatly affecting tirilazad's overall clearance.
March 2025 in “HAL (Le Centre pour la Communication Scientifique Directe)” This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.
January 2025 in “Annals of Dermatology” This review discusses current and emerging treatments for androgenetic alopecia, covering mechanisms, efficacy, and safety of both androgen-targeted and non-androgen-targeted approaches, but reports no new clinical results.
August 2026 in “Canadian Journal of Health Technologies” This study found that Litfulo improved hair regrowth in patients aged 12 and older with severe alopecia areata but did not meaningfully improve anxiety or depression symptoms compared to placebo.
January 2019 in “Nihon Yakuri Gakkai nenkai yoshishu” This article reviews guidelines and medications for treating benign prostatic hyperplasia but presents no new clinical results.
14 citations
,
June 2014 in “World Journal of Urology” This study found that the herbal combination PRO 160/120 significantly improved nocturnal voiding frequency in patients with moderate-to-severe LUTS/BPH compared to placebo, with similar effectiveness to tamsulosin and finasteride.
5 citations
,
July 2021 in “medRxiv (Cold Spring Harbor Laboratory)” This study found that proxalutamide treatment significantly reduced 30-day hospitalization rates in women with mild-to-moderate COVID-19 compared to placebo, with no safety issues identified.
15 citations
,
January 2020 in “RSC advances” In this study, researchers developed a new Supported Ionic Liquid Phase palladium catalyst that showed effectiveness in aminocarbonylation reactions for synthesizing pharmaceutical compounds like CX-546 and a precursor of Finasteride, though results were sensitive to substrate variations and prompted palladium leaching concerns.
This paper provides a comprehensive list of drugs including Ethamolin, Placidyl, Trecator-SC, Zarontin, Peganone, Didronel, and Lodine, detailing their indications, potential interactions, and reported adverse skin reactions, but it presents no new research findings.
22 citations
,
May 2003 in “Planta Medica” This study found that torilin from Torilis japonica fruit extract inhibited 5 alpha-reductase in vitro more effectively than alpha-linolenic acid but less effectively than finasteride.